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ABSTRACT
Objective: To examine medication use in male top-level
football players prior to and during international tourna-
ments.
Design: Prospective survey.
Material: 2944 team physicians’ reports on players’
medication intake.
Methods: Each team physician was asked to document
all medication and nutritional supplements taken in the
72 h prior to each match.
Results: A total of 10 384 substances were reported
(1.8 substances/player/match); 4450 (42.9%) of these
were medicinal and 5934 (57.1%) nutritional supple-
ments. The medications prescribed most frequently were
non-steroidal anti-inflammatory agents (n=2092;
20.1%); more than half of the players took these at least
once during a tournament and more than 10% prior to
every match (156 out of 1472). b-2-Agonists were
reported for 1.4% (n=20) and inhaled corticosteroids for
1.6% (n=23) of participating players. Injected corticos-
teroids were reported for 73 players.
Conclusions: The high intake of medication in interna-
tional football – especially of non-steroidal anti-inflam-
matory drugs – is alarming and should be addressed. The
results raise questions as to whether the medication was
taken solely for therapeutic reasons. In view of the
potential side effects, more restrictive recommendations
for sport need to be developed.
The legal and illegal use of medical substances is
widespread in international sport and is growing
rapidly in its complexity.
1 Most current literature
focuses on illegal substances such as anabolic
steroids,
1 growth hormone,
2 erythropoietin and
blood doping.
3 Although many authors have raised
concerns about the use in international sports of
prescribed substances such as b2-agonists,
4 non-
steroidal anti-inflammatory drugs (NSAIDs),
5–7
corticosteroids,
8 and nutritional supplements,
91 0
only little is known about the magnitude of their
current use.
The main principles in sport concern not only
equality and fairness but also health.
10 11 As such,
the responsibilities of sports associations include
not only the establishment of doping control
networks but also the investigation of legally
prescribed, but potentially harmful medication –
and not only its use in excess.
Previous studies of athletes participating in
the Olympic Games 2000 in Sydney found that
80% of athletes declared using some sort of
medication.
10 A mean intake of 4.6 dietary supple-
ments per player, prescribed medications and over-
the-counter substances were reported for Canadian
athletes.
9
Recently published data on medication use in
professional footballers indicate a high intake of
both supplements
12 and non-steroidal anti-inflam-
matory drugs.
12 13 However, little scientific evi-
dence exists regarding the beneficial effects of
nutritional supplements on sporting perfor-
mance.
14
The Fe ´de ´ration Internationale de Football
Association (FIFA) adopted antidoping measures
in 1970, and since then has continuously developed
its strategy.
1 The low incidence of positive doping
samples in professional football (0.4%) is testa-
ment to the efforts made by FIFA to contain the
problem over the last 40 years.
1 Just before the
FIFA World Cup 1998 in France, FIFA initiated a
new approach, to record the use of medication and
nutritional supplements in each player prior to
each match of a major tournament; to the authors’
knowledge, FIFA is the first international sports
ruling body to introduce such an initiative.
METHODS
Data collection
In connection with the doping controls carried out
in the FIFA World Cup tournaments 2002 and
2006, all team physicians were asked to enter in
English in legible handwriting ‘‘any medication
taken by the players or administered to them in the
72 hours preceding the match… The team doctor
shall also note down any non-prescription medi-
cines or food supplements taken by the players’’.
15
Classification
Based on the information provided by the team
physicians, the active pharmaceutical ingredient of
each reported substance was identified, and the
substance was classified as one of the following:
c Painkilling and anti-inflammatory drugs
– NSAIDs.
51 6
– Analgesics.
– Injected corticosteroids and local anaes-
thetics.
c Muscle relaxants.
c Respiratory agents – anti-asthmatic, antihista-
minic, sympathomimetic medication, and
others.
c Medication for intestinal purposes – proton
pump inhibitors, corticosteroids, and others.
c Antimicrobial medication.
c Others – psychotropic substances, topical
corticosteroids and others.
c Supplements – macronutrients and micronu-
trients, herbal supplements
9 (derivatives from
plant sources), and others.
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Thirty-two countries (23 players each) qualified for each of the
FIFA World Cup tournaments. A total of 64 matches took place
from the qualification round up to the World Cup final, with
three being the lowest number of matches played by any team
for one tournament, and seven being the highest number. Each
World Cup included 2944 player matches.
Data presentation
The incidence of substance intake was calculated as follows:
c substance/player/match
10 (mean intake per player)
c number of individual players reported to be using a
substance
10
c substance/player/tournament
9
Data analysis
The statistical methods applied were frequencies, cross-tabula-
tions and Pearson’s correlation.
We used x
2 tests for comparison of substance categories. 95%
confidence intervals were calculated according the following
formula: 95% CI= incidence ¡1.966 (incidence/square root
(number of incidents)). Statistical significance was accepted at
p,0.05 in all cases.
RESULTS
In the two FIFA World Cups, a total intake of 10 384 substances
was documented, of which more than half (57.2%) were
classified as nutritional supplements. The average consumption
per player was 1.8 substances (0.8 medications) prior to each
match (see fig 1). Some individual players took as many as seven
different substances or five of the seven different substance
groups prior to a match.
During the two tournaments, 44.0% of the players took at
least one type of medication prior to a match, and 68.5% during
the tournament; 19.7% of players had no medication intake (see
table 1).
Non-steroidal anti-inflammatory drugs and analgesics
NSAIDs were the most frequently prescribed substances,
accounting for almost half of all reported medicines used
(2002: 46.5%, 2006: 47.7%). More than half of the players took
NSAIDs at least once during a tournament and 30.8% prior to a
match. On average, 22.9% of the players (2002: n=183; 2006:
n=154) were using NSAIDs in two out of three matches, and
10.6% of the players (2002: n=80; 2006: n=76) were taking
them prior to every match. Substantial differences were
observed between the countries; in one team 22 out of 23
players took NSAIDs prior to every match (for details, see
table 2).
More than 10% of the players taking NSAIDs were using at
least two preparations prior to a match (2002: n=125; 2006:
n=102); in some players, as many as five different preparations
were taken. Diclofenac was the most frequently reported active
pharmaceutical ingredient (2002: n=536 (48.2%); 2006: n=550
(55.2%)), followed by Ketoprofen (2002: 150 (13.5%); 2006: 84
(8.6%)). The use of COX-2 inhibitors decreased from 2002 to
2006 (191 (17.2%) versus 101 (10.3%); p,0.001). Acetylsalicylic
acid was rarely reported (2002: 30 (2.7%); 2006: 19 (1.9%)).
Other analgesics represented 5.5% of all prescribed medicines.
Medications for the respiratory tract
Substances acting primarily on the upper and lower respiratory
tract were the second most frequently prescribed substances
(2002: 7.2%; 2006: 13.8%), with antihistamines being the most
common of these, accounting for 40.7% (n=186), followed by
b2-agonists (n=72, 15.8%), antitussives (n=63, 13.3%),
inhaled corticosteroids (n=54, 11.8%), a-sympathomimetic
agents (n=52, 11.4%) and others (n=30, 6.6%).
During the two tournaments, 11 players were reported to be
using b2-agonists and NSAIDs together on 23 occasions.
Corticosteroids
Corticosteroids – accounting for 7.2% of all medications – were
mainly injected (n=112, 35.2%) and used as ointments (n=92,
28.9%). Other medical indications, such as for ears and eyes
(n=55, 17.3%), respiratory tract (n=54, 17.0%) and gastro-
intestinal problems (n=5, 1.6%) were less frequent.
Others
In nearly 80% cases (119 out of 150), gastric protectors such as
proton pump inhibitors (2002: n=30; 2006: n=21), prosta-
glandins (2002: n=54; 2006: n=32) and others (2002: n=13;
2006: n=0) were reported in combination with non-steroidal
anti-inflammatory drugs.
Injections of local anaesthetics were reported 72 times in
2002 and 76 times in 2006.
Of all reported psychotropic substances, 94.1% were narcotics
(2002: n=111 of 118 cases, including 34 non-benzoic agents;
2006: 64 of 68 cases, including 24 non-benzoic agents); only
three players were reported to use antidepressants.
Figure 1 Prescribed medication during FIFA World Cup 2002 and 2006.
*Corticosteroid and local anaesthetic injections only.
Table 1 Number of players with reported medication and use of
nutritional supplements
WC 2002 WC 2006
No. of players No. of players
Per match
During
tournament Per match
During
tournament
(n=2944) (%) (n=736) (%) (n=2944) (%) (n=736) (%)
Any medication 1335 (45.3) 500 (67.9) 1257 (42.7) 508 (69.0)
NSAIDs 960 (32.6) 403 (54.8) 855 (29.0) 399 (54.2)
Injections* 120 (4.1) 77 (10.5) 103 (3.5) 58 (7.9)
Analgesics 131 (4.4) 91 (12.4) 108 (3.7) 83 (11.3)
b-2-Agonists 34 (1.2) 8 (1.1) 31 (1.1) 12 (1.6)
Antihistamines 60 (2.0) 43 (5.8) 106 (3.6) 55 (7.5)
Any
supplement
925 (31.4) 314 (42.7) 1041 (35.4) 317 (43.1)
Any substance 1809 (61.4) 582 (79.1) 1868 (63.5) 600 (81.5)
*Corticosteroid and local anaesthetic injections only.
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Significantly more nutritional supplements were prescribed in
2006 (1.28; 95% CI 1.25 to 1.33 supplements/player/match)
than in 2002 (0.73; 95% CI 0.70 to 0.76; see fig 2): vitamins
represented the majority (41.1%), followed by minerals (21.2%)
and amino acids (11.1%).
Iron supplementation represented 11.8% of the prescribed
minerals — substantially less than the mineral complexes
(56.6%) and magnesium (20.6%). Of the amino acids, poly-
amino-acids were most often used (41.2%) followed by arginine
(24.4%) and glutamine (22.0%). Ginseng supplementation
represented more than half of the prescribed herbal and
homeopathic substances (54.6%, 219 out of 401); preparations
containing guarana (17.2%, 69) and arnica (11.5%, 46) were
rarely used. Caffeine was reported as being used by two players
in 2002 and four in 2006.
Some players were reported to take as many as ten different
supplements prior to a game, and one team reported an average
prescription of 7.4 nutritional supplements per player, per
match during the FIFA World Cup 2006.
Relation to team success and player exposure
For both tournaments, there was no significant correlation
between the final ranking of the team and the mean number of
medications taken per match, the mean intake of NSAIDs per
match, or the mean intake of any substance per match (r between
20.15 and +0.06). Low but statistically significant correlations
were found between a player’s average playing time per match
and the mean number of medications taken per match (2002:
r=+0.14, p,0.001; 2006: r=+0.16; p,0.001) and between the
average playing time per match and mean intake of NSAIDs per
match (2002: r=+0.14; p,0.001; 2006: r=+0.18; p,0.001).
DISCUSSION
Sport in general has consistently been shown to have beneficial
health effects, resulting in fewer medical consultations
17 and a
lower use of medication in physically active people.
18
Top athletes, however, face a higher incidence of osteoar-
thritis and greater risk of injury than employees in most other
occupations.
19 Competing athletes also seem to have a higher
intake of medication than non-competing athletes.
18 20
Mottram
21 postulated that there are four types of medication
use in professional athletes: legitimate therapeutic use, perfor-
mance continuation (treatment of sports injuries), recreational/
social use, and performance enhancement. Athletes trying to
enhance their performance by taking pharmaceutical agents and
large quantities of nutritional supplements are predominantly
healthy athletes.
22
Whilst the present study was able to document the
prevalence of medication use in top athletes, it was not able
to scrutinise the underlying motivations for, or the likely
implications of, such use.
The present results show a widespread use of prescribed
medicines in professional football, with 0.8 substances per
player per match being reported. NSAIDs represented nearly 50
percent of all substances, with one in three players being
prescribed NSAIDs prior to a match, one in ten taking two or
more different preparations, and some taking as many as five
different preparations.
No relationship was observed between team success and the
amount or type of prescribed medication. However, players with
ahigh average playingtimewereprescribedmoremedications and
more NSAIDS per match than were substitutes.
A wide range was reported for nutritional supplement use (0–
7.4 nutritional supplements per player, per match), with as
many as ten different substances being taken prior to a match in
some cases. Coaches have been found to have a greater influence
than doctors and sports dieticians on the nutritional supple-
ments taken by athletes;
12 this could have biased the figures of
intake reported by the team physicians.
Earlier studies have analysed the use of prescription medicines
and nutritional supplements in national Olympic squads
participating in winter and summer sports,
92 3in athletes during
the Olympic Games (OG) (information gained from doping
controls)
10 and in professional soccer players during one
season.
13 In the latter study, data were collected from personal
interviews with the athletes themselves.
13 This differs from the
method employed in the present study, in which information
was obtained solely from the team physicians; further – but
similarly to the investigation conducted by Corrigan et al
10 –i n
the present study, information was collected for each partici-
pating player, prior to every match.
Compared with the information acquired during the doping
controls at the Olympic Games in Sydney,
10 significantly more
football players did not use any substance (22% in Sydney vs.
38% here); however, more were reported to use NSAIDs. Similar
results to the present study were found in Finnish athletes
participating in the Winter Olympic Games.
23 In professional
football players in Italy, however, 86% were reported to be
current NSAIDs users.
13
As reported previously,
10 antiasthmatic medication is rarely
prescribed in international football. In the present study, 2.2% of
all players (ten players treated with b-2-agonists, 13 with inhaled
corticosteroids and ten with combined therapy) were being
treated for asthma; this compares with 5.2% (607 out of 10 672)
during the OG 2000
4 (p,0.001), 4.2% (445 out of 10 653) during
the OG 2004
4 (p,0.001) and 7.0% (31 out of 446) of all Finnish
athletes competing at the Winter OG 2002(p,0.001).
23
A total of 148 injections of local anaesthetic were reported,
that is, nearly 1.2 injections per match. Similar incidences have
been reported for rugby and for Australian rules football (1.7
and 1.4 injections per match, respectively).
24
Although there are reports of a high prevalence of sustained
adverse effects with NSAID use in athletes
23 and alternative
substances are well-known,
62 5 the indication for NSAIDs
appears to have been broadened to almost any painful
condition.
26 The current literature does not provide any
conclusive evidence to justify this high usage. On the one hand,
the pain-relieving qualities of NSAIDs are uncontested;
5
however, their influence on the healing process is controversial
5
and their adverse effects in sport, for example in the context of
dehydration and the kidney, are not fully understood.
7 The
Figure 2 Reported use of nutritional supplements during FIFA World
Cup 2002 and 2006. *Antioxidants, caffeine, CoQ10, essential fatty
acids, taurine and others.
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21 27
and pharmacological variables.
5 Animal studies have found
potentially deleterious effects of NSAIDs on the healing
process.
28 Porucznik et al found a higher prevalence of
suprascapular neuropathy in collegiate volleyball players who
used NSAIDs than in athletes who did not.
29 Paolini and
Orchard
6 discussed the issue of soft-tissue injuries and
concluded that paracetamol had similar efficacy to NSAIDs in
soft-tissue injury but had a lower side-effect profile. The
authors concluded that paracetamol is the analgesic of choice
for most soft tissue injury.
6
The NSAID guidelines from the National Health Service
16
recommend:
c Lowest possible dose and for shortest possible period.
c One preparation at a time.
c Prudent application in asthmatic patients.
c Avoid long-term use.
c Lowering gastrointestinal adverse effects by paracetamol
with or without codeine.
c Use gastroprotective agents and or/COX-2 inhibitors in
patients at high risk of gastrointestinal bleeding for whom
NSAID therapy is necessary.
These therapeutic recommendations have not yet been
adopted in international football. In the present study, more
than one in ten players taking NSAIDs were using at least two
preparations, NSAIDs were used 8.5 times more frequently
than other analgesics, 10% of all players used NSAIDs prior to
each of their matches, and 11 players were using antiasthmatic
medication and NSAIDs at the same time. These findings are
not unique to football, however.
10 23 29
The substantial variation in the participating teams’ reported
medication use – especially with respect to NSAIDs – highlights
the difference in therapeutic concepts that currently exists in
sports medicine; the majority are most likely based on
individual empirical evidence or experience rather than on any
firm evidence base.
In general, nutritional supplementation is not considered
necessary, for either nutritional or immunological reasons, in
athletes with an ‘‘adequate’’ diet.
30 Additionally, there is not
only the possibility of contamination,
31 but also the potential
for detrimental effects if different substances are misleadingly
taken in excess.
30 When competing at top level, therefore,
professional advice on the quality and quantity of supplementa-
tion is essential.
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. What this study adds
Professional football players—mostly healthy athletes—consume
a considerable quantity of medication, especially non-steroidal
anti-inflammatory drugs, prior to competition. These alarming
results should initiate debate on the prescription and indications
for medication in sport.
What is already known on this topic
In the literature to date, the main focus of drug use in professional
football players has been on doping substances. However, the
extent of the use of ‘‘legally’’ prescribed medication—which may
have just as detrimental an effect on the player’s health—is
largely unknown in professional football.
Original article
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The high intake of non-steroidal anti-inflammatory drugs
reported during consecutive FIFA World Cups is difficult to
interpret, since the differentiation between indication, wrong
application and misuse of prescribed medication is difficult to
ascertain. Since the current literature does not support the
extensive use of NSAIDs as a painkilling agent, dialogue with
the treating physicians should be initiated, to provide a better
understanding of this issue. Furthermore, prospective clinical
studies should be carried out, especially within the context of
analgesic use, in order to develop better, evidence-based
recommendations for the treatment of sports injuries.
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